secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001641172-25-017052
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera acquires US Ameluz/RhodoLED rights, cuts royalty to 12%, gets $11M financing
--------------------------------------------------------------------------------

- Acquires all US assets for Ameluz and RhodoLED including NDA and patents from Biofrontera AG.
- Effective royalty rate reduced from 25-35% of net sales to 12% (15% above $65M revenue).
- Receives $11M investment led by Rosalind Advisors and AIGH Capital Management, funding to profitability.
- Biofrontera AG to receive 10% post-money equity stake in Biofrontera Inc., aligning long-term interests.
- First tranche of $8.5M funded at signing; second tranche of $2.5M due upon final asset transfer agreement by Sep 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000164117225017052/0001641172-25-017052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000164117225017052/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-017052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer